Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony S Mok

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2013
Epidermal growth factor receptor inhibition in lung cancer: status 2012Fred R Hirsch, Pasi A Jänne, Wilfried E Eberhardt, et al.
Clinical Lung Cancer|May 5, 2010
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma componentWen-Zhao Zhong, Yi-Long Wu, Xue-Ning Yang, et al.
The Lancet. Oncology|September 30, 2017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi-Long Wu, Ying Cheng, Xiangdong Zhou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 9, 2016
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment RegimensLuis Paz-Ares, Vera Hirsh, Li Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2021
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)Ying Cheng, Tony S Mok, Xiangdong Zhou, et al.
The New England Journal of Medicine|December 14, 2016
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerTony S Mok, Yi-Long Wu, Myung-Ju Ahn, et al.
The New England Journal of Medicine|August 21, 2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S Mok, Yi-Long Wu, Sumitra Thongprasert, et al.
Journal of Cancer Research and Clinical Oncology|May 5, 2007
KDR expression is associated with the stage and cigarette smoking of the patients with lung cancerShe-Juan An, Qiang Nie, Zhi-Hong Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2014
Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationJin-Ji Yang, Xu-Chao Zhang, Jian Su, et al.
Journal of the National Cancer Institute|October 20, 2005
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinomaWinnie Yeo, Tony S Mok, Benny Zee, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2013
Epidermal growth factor receptor inhibition in lung cancer: status 2012Fred R Hirsch, Pasi A Jänne, Wilfried E Eberhardt, et al.
Clinical Lung Cancer|May 5, 2010
Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma componentWen-Zhao Zhong, Yi-Long Wu, Xue-Ning Yang, et al.
The Lancet. Oncology|September 30, 2017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi-Long Wu, Ying Cheng, Xiangdong Zhou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 9, 2016
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment RegimensLuis Paz-Ares, Vera Hirsh, Li Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2021
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)Ying Cheng, Tony S Mok, Xiangdong Zhou, et al.
The New England Journal of Medicine|December 14, 2016
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerTony S Mok, Yi-Long Wu, Myung-Ju Ahn, et al.
The New England Journal of Medicine|August 21, 2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S Mok, Yi-Long Wu, Sumitra Thongprasert, et al.
Journal of Cancer Research and Clinical Oncology|May 5, 2007
KDR expression is associated with the stage and cigarette smoking of the patients with lung cancerShe-Juan An, Qiang Nie, Zhi-Hong Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2014
Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationJin-Ji Yang, Xu-Chao Zhang, Jian Su, et al.
Journal of the National Cancer Institute|October 20, 2005
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinomaWinnie Yeo, Tony S Mok, Benny Zee, et al.
Pageof 5